Press releases

December 28, 2016 Invitae to present at the 35th Annual J.P. Morgan Healthcare Conference
Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that members of the company's management team will present at the 35th Annual J.P. Morgan Healthcare conference on Wednesday, January 11, 2017 at 2:30 p.m. Pacific at The Westin St. Francis in San Francisco . The live, listen-only webcast of both the presentation and breakout session immediately following may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company's website. About Invitae Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time, and lower price than
Read more
December 21, 2016 Invitae announces major expansion of its pediatric, neurological, and rare disease genetic test offerings
- New and expanded panels allow clinicians to screen for genetic changes associated with epilepsy, developmental disorders, and a variety of other pediatric, neurological, and rare conditions - SAN FRANCISCO, December 21, 2016 - Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the availability of 24 new and 19 expanded genetic test panels, allowing clinicians to gain information on 183 new genes with clinical and diagnostic significance. This launch represents a significant expansion of the company’s pediatric, neurological, and rare disease offerings, which include tests for genes associated with epilepsy, developmental disorders, overgrowth syndromes, and skeletal disorders, as well as tests in dermatology, immunology, and ophthalmology. The panels provide clinicians, patients, and payers greater flexibility to access high-quality, affordable genetic information across a larger number of pediatric and neurological disorders, as well as rare diseases,
Read more
December 14, 2016 Invitae Sees Increase in Utilization of Its Inherited Prostate Cancer Genetic Tests
- High quality, comprehensive, affordable genetic tests designed to ensure access for prostate cancer patients who may benefit from broader panel testing, including BRCA1, BRCA2, and other genes associated with prostate cancer - Invitae Corporation (NYSE:NVTA), one of the fastest growing genetic information companies, has seen a significant increase in genetic testing for prostate cancer since the publication of landmark data showing testing may be underutilized when screening for and treating the second most common cancer in men. The company’s panel is the most comprehensive and affordable genetic test available to urologists and oncologists who treat men with prostate cancer, establishing the company as a new leader in prostate cancer testing. According to a study in the New England Journal of Medicine (NEJM) , the incidence of germline mutations in men with metastatic prostate cancer is over 11% – higher than the historical rate for BRCA1 and BRCA2 mutations in high-risk breast
Read more
December 8, 2016 Invitae and TME Research Announce Landmark New Study to Evaluate Universal Genetic Testing of Breast Cancer Patients
Invitae Corporation (NYSE:NVTA) , a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the benefits of universal genetic testing of breast cancer patients. TME Research represents more than 300 breast care practices around the country whose core mission is to improve the quality and access to targeted breast cancer care. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161208005328/en/ The collaboration, called the Universal Breast Cancer Genetic Testing Registry, will enroll 1,000 breast cancer patients across 20-25 TME practices in the United States . The enrollees will be tested with Invitae’s multi-cancer panel, an 80-gene hereditary cancer test that includes genes associated with hereditary cancers in eight major organ systems. Any patient with a current or previous diagnosis of breast cancer will be asked to consent to be enrolled in the
Read more
December 7, 2016 Invitae Adds Two Genes, Offers Faster Turnaround Time for Its Breast Cancer STAT Panel
- Now providing a faster and more comprehensive panel for patients with breast cancer who need rapid test results to guide surgical decisions - Invitae Corporation (NYSE:NVTA), a genetic information company, today announced the expansion of its Breast Cancer STAT Panel with the addition of two important breast cancer predisposition genes – ATM and CHEK2 – and a faster turnaround time (TAT) with results available in as few as five days at no additional cost. The announcement was made at the San Antonio Breast Cancer Symposium (SABCS). “Recent research underscores the clinical utility of ATM and CHEK2 in making treatment decisions, and many of our provider clients have requested these genes be included,” said Robert Nussbaum , MD, chief medical officer of Invitae . “The addition of these genes to Invitae’s Breast Cancer STAT Panel provides clinicians with more comprehensive information without sacrificing time for results, ultimately supporting better patient care for patients and
Read more
November 17, 2016 Invitae to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that members of the company’s management team will present at the Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17, 2016 at approximately 3:00 p.m. Eastern at the Westin Grand Central in New York City . The live, listen-only webcast of the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company’s website. About Invitae Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The
Read more
November 17, 2016 Invitae Announces Pricing of Public Offering of Common Stock
Invitae Corporation (NYSE:NVTA) today announced the pricing of an underwritten public offering of 7,333,333 shares of its common stock at a price to the public of $6.00 per share. All of the shares are being sold by Invitae . The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $44 million . The offering is expected to close on or about November 22, 2016 , subject to customary closing conditions. In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 1,099,999 shares of its common stock at the public offering price, less the underwriting discounts and commissions. J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Cowen and Company, LLC is acting as a co-manager for the offering. A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and
Read more
November 15, 2016 Invitae Announces Proposed Public Offering of Common Stock
Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $40 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae . In addition, Invitae expects to grant the underwriter a 30-day option to purchase up to an additional $6 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on June 20, 2016 . The offering is being made solely by means of a prospectus. A copy of
Read more
November 7, 2016 Invitae Announces Third Quarter 2016 Financial Results, Secures Contracts With Top Five Largest Payers, and Grows Volume More Than 200% Year-Over-Year
SAN FRANCISCO-(BUSINESS WIRE)- Invitae Corporation (NYSE: NVTA), a genetic information company, today announced financial and operating results for the third quarter ended September 30, 2016. Year to date, the company has secured contracts with the top five major payers while making substantial progress on all four of its key metrics. The company also stated it expects to be cash flow positive by the end of 2018. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161107006497/en/ (Graphic: Invitae Corporation) “We believe Invitae has emerged from being a concept story to a company that has industry-leading growth rates in the genetic testing market with a clear path to becoming cash flow positive,” said Randy Scott , chairman and chief executive officer at Invitae . “With our recently announced progress in contracting with the top five major payers, we are now shifting our emphasis to driving revenue as a top priority. We
Read more
October 24, 2016 Invitae to Announce Third Quarter 2016 Financial Results and Host Conference Call on November 7, 2016
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that it will report its third quarter 2016 financial results on Monday, November 7, 2016 and will host a conference call that day at 4:45 pm Eastern / 1:45 pm Pacific to discuss its financial results and recent developments. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 5259406. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company’s website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website. About Invitae Invitae Corporation’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of
Read more
October 19, 2016 Invitae Announces Multiple Scientific Presentations and Posters to Be Presented at the American Society of Human Genetics 2016 Annual Meeting
- 14 posters and presentations to focus on advances in genetic testing technology and medical interpretation tools as well as new applications of genetics in health and wellness - This week Invitae Corporation (NYSE: NVTA), a genetic information company, is presenting multiple abstracts at the American Society of Human Genetics (ASHG) 2016 Annual Meeting in Vancouver, covering an array of topics in genetics, including advances in complex variant detection and medical interpretation, as well as survey data exploring the attitudes of healthy adults seeking genetic testing through their physicians and the frequency with which medical guidance accompanies the results. “The use of genetic information to better understand and diagnose disease and to guide treatment choices expands significantly each year,” said Robert Nussbaum , MD, chief medical officer of Invitae . “The research presented at this year’s ASHG meeting moves us another step forward in our scientific knowledge and
Read more
October 18, 2016 Invitae Announces Collaboration With Helix to Build Applications for Health and Wellness
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced a collaboration with Helix, a personal genomics company, to build novel, clinician-approved genetic testing applications designed to work with Helix’s CLIA-certified DNA sequencing platform to provide screening applications for health and wellness. Individuals who utilize the Helix consumer platform will be able to select health applications from Invitae pending approval by a clinician. Invitae will then provide a full interpretation of the results. Through this collaboration, Invitae will offer some of the first health apps on the Helix platform for common, actionable inherited disorders. The Invitae apps will be designed to provide healthy individuals with a proactive genetic health scan focused on risk factors for common diseases for which there are preventive measures available. The collaboration will initially focus on common, actionable genes associated with inherited forms of cancer and
Read more
October 3, 2016 Invitae Announces Final Medicare Pricing Set at $925 for Hereditary Breast Cancer-Related Disorders Under New Billing Process
Invitae Corporation (NYSE: NVTA) , a genetic information company, announced that the Centers for Medicare and Medicaid Services (CMS) announced final pricing for genetic testing for hereditary breast cancer-related disorders (e.g. hereditary breast cancer, hereditary ovarian cancer, and hereditary endometrial cancer). The tests are billed under the new current procedure terminology (CPT) code 81432, which became effective on January 1, 2016 . CMS had previously announced a temporary payment per test of $622.53 , and - after a public comment period - the final payment per test is now set at $925 . Payments are made by Noridian, CMS’s administrative contractor for California . “We applaud this historic transition by Medicare which makes genetic testing more affordable and accessible for patients with hereditary breast cancer related disorders,” said Randy Scott, chief executive officer of Invitae. “In the past year, Medicare and the Palmetto MolDX program have significantly reduced the
Read more
September 30, 2016 Genetic Counselors Recognized by Patients, Peers for Excellence in Patient Care
- Finalists and winner for Genome magazine’s Code Talker Award announced and honored at the National Society of Genetic Counselors (NSGC) Annual Education Conference - At the National Society of Genetic Counselors (NSGC) Annual Education Conference in Seattle, Allison Goetsch, MS, CGC, genetic counselor at Ann & Robert H. Lurie Children’s Hospital of Chicago was announced as the winner of the inaugural Code Talker Award. The Code Talker Award, sponsored by Invitae Corporation (NYSE: NVTA), was established by Genome magazine to recognize the impact genetic counselors have on the health and lives of patients. Also honored at NSGC were Amie Blanco , MS, LCGC, genetic counselor and acting director at the UCSF Cancer Genetics and Prevention Program, part of the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco , and Anna Victorine , MS, CGC, genetic counselor at Provenance Healthcare in Las Vegas , who were both named as finalists. Chosen from scores of nomination
Read more
September 28, 2016 Invitae Presenting Research on Genetic Test Panels, Increasing Access to Genetic Counseling at the National Society of Genetic Counselors 35th Annual Education Conference
This week Invitae Corporation (NYSE: NVTA) , a genetic information company, is participating in the National Society of Genetic Counselors (NSGC) 35th Annual Education Conference in Seattle , highlighting new research on genetic testing for preventive care and new strategies for providing remote access to genetic counseling services. NSGC is the largest scientific session for genetic counselors. Invitae’s presenters will discuss: The role of genetic testing in guiding preventive care is an area of keen interest for many patients and their primary clinicians. A presentation describing a medically actionable genetic test panel aimed at supporting prevention of disease will outline a model for how preventive genetic testing should be provided and can yield useful results for healthy patients (Presentation #D12-1377). Interest in genetic testing continues to rise, but the number of genetic counselors has not kept pace with demand, creating significant challenges for patients in need of
Read more
August 15, 2016 Invitae Announces Major Expansion of Its Neurology and Cardiology Test Offerings
- Introduces new panels for Parkinson’s disease, neuropathies, and neuromuscular diseases - - Adds new genes to panels for arrhythmias, cardiomyopathies, aortopathies, and congenital heart disease; introduces a new cardiomyopathy and skeletal muscle disease panel - Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that it has expanded its neurology and cardiology test offering, adding 11 new panels for heritable diseases. In addition, Invitae has updated 17 existing neurology panels and eight cardiology panels based on new discoveries in genetics research. With this latest expansion of its test offerings, Invitae will be able to provide clinicians, patients, and payers with even higher-quality information on genetic changes that have been shown to influence a variety of neurologic and cardiovascular disorders – for the same price and with the same three-week average turnaround time. The new panels will be available immediately to children’s hospitals,
Read more
August 8, 2016 Invitae Announces Second Quarter 2016 Financial Results, Secures Contract with a National Payer and Expands Its Network of Regional Private Payers
– Accelerated development of a 20,000-gene medical exome to be available in Q1:2017 – – Nearly tripled volume with more than 12,000 test reports delivered – – Lowered COGS to approximately $500 – – Signed first biopharma agreements – – Hosting webinar/conference call at 4:45 pm ET / 1:45 pm PT – Invitae Corporation (NYSE: NVTA), a genetic information company, today announced financial and operating results for the second quarter ended June 30, 2016. The company made substantial progress on all four of its key metrics, including securing contracts with a major national payer and adding more regional private plans. The company also announced it is accelerating the development of its medical exome, to be comprised of more than 20,000 genes, which it expects will be available in the first quarter of 2017. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160808006131/en/ “Today we are announcing that we will be ‘leapfrogging’
Read more
July 28, 2016 Invitae to Present at the Canaccord Genuity 36th Annual Growth Conference
Invitae Corporation (NYSE:NVTA) , a genetic information company, today announced that members of the company’s management team will present at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016 at approximately 12:30 p.m. Eastern in Boston . The live, listen-only webcast of the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company’s website. About Invitae Invitae Corporation's (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic service
Read more
July 25, 2016 Invitae to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 8, 2016
Invitae Corporation (NYSE:NVTA) , a genetic information company, today announced that it will report its second quarter 2016 financial results on Monday, August 8, 2016 and will host a conference call that day at 4:45 pm Eastern / 1:45 pm Pacific to discuss its financial results and recent developments. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 48736029. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company’s website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website. About Invitae Invitae Corporation's (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of
Read more
July 20, 2016 Invitae Introduces New Breast Cancer STAT Panel for Patients With Breast Cancer Who Need Rapid Test Results to Guide Surgical Decisions
- Test offers rapid turnaround time on seven genes that may influence surgical options and treatment decisions - Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company now offers a new Breast Cancer STAT Panel of high-quality genetic testing designed for breast cancer patients whose providers need a fast turnaround time to guide treatment and management. Invitae’s new Breast Cancer STAT Panel includes seven genes with surgical and therapeutic relevance: BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, and TP53. Mutations in these seven genes have been shown to increase a patient’s risk of breast cancer significantly and may influence the patient and physician choice between mastectomy and lumpectomy, whether to perform prophylactic salpingo-oophorectomy, and may inform choice of chemotherapy, including PARP inhibitors. Testing is available for blood and saliva samples, and results are available within 8-12 calendar days. "This is the kind of
Read more
June 28, 2016 Invitae Contributes More Than 10,000 Additional Genetic Variants to the ClinVar Project
- Contribution helps ensure genetic information is widely and freely available for peer-review in order to establish a new “gold standard” and to help clinical researchers improve healthcare - - Brings the company’s total contribution to more than 22,000 variants submitted - Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that the company has submitted information on more than 10,000 clinically observed genetic variants to the ClinVar project , an effort by the National Center for Biotechnology Information (NCBI) to aggregate all of the world’s known relationships between genetic variants and disease, bringing our total submissions to more than 22,000. ClinVar is a freely available archive of submissions from across the world of variants and their interpretations by the lab that observed them. “We believe that genetic information is more valuable when shared and that submitting clinical variants to ClinVar is rapidly becoming the new gold standard for
Read more
June 23, 2016 Genome Magazine Kicks Off “Code Talkers” National Essay Contest to Honor Genetic Counselors, Sponsored by Invitae
- Clinicians, patients and families invited to submit essays recognizing the impact of genetic counselors - - Finalists to be featured in a book and honored at National Society of Genetic Counselors (NSGC) Annual Education Conference - People across the U.S. are sharpening their pencils and honing their writing skills by taking part in Genome magazine’s Code Talker Award, an essay contest in which patients and their families pay tribute to a genetic counselor by nominating him or her for an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160623005235/en/ In April, Genome magazine and the NSGC kicked off the Code Talker Award contest and will accept essays until June 30, 2016 . The magazine is seeking nominations from patients, caregivers, and peers detailing the compassion, expertise, and
Read more
June 6, 2016 Invitae Announces the Launch of CancerCHECK to Guide and Support Community Oncologists Through the Hereditary Cancer Genetic Testing Process
- New tool launched at the 2016 ASCO Annual Meeting along with presentation of new data underscoring the importance of genetic testing in cancer care - To help community oncologists more easily follow clinical guidelines on the use of genetic testing, Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the availability of CancerCHECK (Cancer Complete Hereditary Evaluation Clinic Kit), a comprehensive support program. CancerCHECK provides checklists, information, and customized support free of charge for clinicians considering genetic testing for hereditary breast, ovarian, and colorectal cancers. The company made the announcement alongside new data on genetic testing in cancer presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. CancerCHECK Helps Clinicians Easily Follow Guidelines CancerCHECK provides step-by-step support for clinicians using genetic testing: Checklist to identify appropriate candidates for genetic
Read more
May 31, 2016 Invitae Now Offers Comprehensive, High-Quality, Affordable Genetic Testing in New York for Hereditary Cancer, Cardiology, and Epilepsy
- Company received approval from New York State Department of Health - - Expands customer base by over 19 million people - Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that the company has completed the comprehensive Clinical Laboratory Evaluation Program and received its clinical laboratory permit from the state of New York . With this approval, Invitae now offers genetic testing in all 50 states, Canada , and other countries in the following test categories: Hereditary cancer: Invitae has one of the most comprehensive hereditary cancer testing menus, which includes testing for breast, gynecologic, ovarian, uterine, colorectal, gastric, pancreatic, endocrine, gastrointestinal, genitourinary, hematologic, nervous system/brain, sarcoma, and skin cancers Cardiology: Invitae’s cardiology menu analyzes approximately 190 genes for arrhythmias, cardiomyopathies, aortopathies, familial hypercholesterolemia, pulmonary hypertension, and congenital heart
Read more
May 11, 2016 Invitae to Present at the UBS Global Healthcare Conference
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that members of the company’s management team will present at the UBS Global Healthcare Conference on Monday, May 23, 2016 at approximately 3:00 p.m. Eastern / 12:00 p.m. Pacific in New York City . The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the company’s website. About Invitae Invitae Corporation's (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic
Read more
May 9, 2016 Invitae Announces First Quarter 2016 Financial Results
SAN FRANCISCO-(BUSINESS WIRE)- Invitae Corporation (NYSE: NVTA), a genetic information company, today announced financial and operating results for the first quarter ended March 31, 2016. The company executed on all four of its key metrics, including important progress on reimbursement. “We made significant strides on reimbursement early this year with payments initiated from Medicare , as well as new contracts with several Blue Cross Blue Shield regional plans,” said Randy Scott , chairman and CEO of Invitae . “We believe this is just the start of a major transition in the payer industry toward more affordable and accessible genetic testing, resulting from major advances in DNA sequencing technology and the rapid adoption of multi-gene panels into clinical guidelines and medical practice.” The company reported total revenue of $4.0 million in the first quarter of 2016, compared to $1.2 million in the first quarter of 2015. Operating expenses, excluding the costs of tests delivered,
Read more
April 28, 2016 Invitae to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that members of the company’s management team will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Thursday, May 12, 2016 at approximately 8:00 a.m. Pacific in Las Vegas . The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcasts will be available shortly after the conclusion of the presentation and will be archived on the company’s website. About Invitae Invitae Corporation's (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a diagnostic
Read more
April 25, 2016 Invitae to Announce First Quarter 2016 Financial Results and Host Conference Call on May 9, 2016
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that it will report its first quarter 2016 financial results on Monday, May 9, 2016 and will host a conference call that day at 4:45 pm Eastern / 1:45 pm Pacific to discuss its financial results and recent developments. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 92101487. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company’s website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website. About Invitae Invitae Corporation's (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the
Read more
April 19, 2016 Invitae Announces Medicare Reimbursement for Hereditary Breast Cancer-Related Disorders Under a New CPT Code for Multi-Gene Panels
- Medicare’s MolDX policy expected to result in cost saving for hereditary cancer testing - Invitae Corporation (NYSE:NVTA), a genetic information company, announced that the Centers for Medicare and Medicaid Services (CMS) have begun providing payments for Invitae’s multi-gene tests for hereditary breast cancer-related disorders (e.g. hereditary breast cancer, hereditary ovarian cancer, and hereditary endometrial cancer). The tests are billed under the current procedure terminology (CPT) code 81432, which became effective on January 1, 2016. Payments are made by Noridian, CMS’s administrative contractor for California. The payments reflect a decision by the Palmetto MolDX program, the Medicare contractor that determines molecular testing policy in about 20 states, including California . According to their recently published guidance titled “ Next Generation Sequencing (NGS) and Tier 1 and Tier 2 Coding and Billing Guidelines (M00130, V2) ,” CPT code 81432 should be used for tests
Read more
April 1, 2016 Invitae Presented Data at the NCCN Annual Conference on the Utility of Multi-Gene Panels
- Company offers multi-gene panels based on NCCN guidelines to help clinicians select tests for their individual patients - Invitae Corporation (NYSE:NVTA), a genetic information company, presented data on its guidelines-based genetic testing panels at the NCCN Annual Conference: Advancing the Standard of Cancer Care in Hollywood, Florida, on Thursday. Invitae offers guidelines-based panel testing that clinicians can customize to reflect their own diagnoses and expertise to ensure that clinicians have the right tests for the right patients. “We have entered an era where testing for BRCA1 and BRCA2 alone is inadequate,” said Peter Beitsch , MD, FACS, surgical oncologist, Director of the Dallas Breast Center , and past president of the American Society of Breast Surgeons (ASBS). “Inherited pathogenic mutations in many other genes lead to breast (and other) cancers and these genes should also be evaluated in patients who qualify for traditional BRCA1/2 testing. This speaks to the
Read more
March 29, 2016 Invitae Announces Major Expansion of Its Test Menu for Neurological, Pediatric, and Rare Genetic Conditions and Introduces New Panels for Inherited Metabolic Disorders and Newborn Screening Confirmation
SAN FRANCISCO-(BUSINESS WIRE)- Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and expanded panels for neurology, pediatrics, and rare diseases. Invitae also has introduced an entirely new clinical testing area designed to complement newborn screening for metabolic and immunological conditions. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160329005578/en/ Invitae expands its comprehensive, high-quality, affordable genetic tests (Graphic: Business Wire) With this expanded test menu, Invitae will be able to provide clinicians, patients, and payers with high-quality genetic information for a greatly expanded number of genes and disorders, all at the same price and with the same three-week average turnaround time. The new panels will be available immediately to children’s hospitals, pediatricians, and
Read more
March 10, 2016 New Data on Rare Diseases Demonstrate Impact of Delayed Diagnosis and Obstacles for Patients and Clinicians, Including Lack of Information, Time to Diagnosis, and Accessibility Due to Cost
Data honored and presented at the 2016 ACMG Annual Clinical Genetics Meeting Invitae Corporation (NYSE:NVTA), a genetic information company, today presented data showing that both patients and clinicians in the rare disease community face significant obstacles navigating the diagnosis of rare disease. The poster titled “Rare Disease Diagnosis Obstacles: Patient Perspectives and Physician Findings” has been acknowledged by the American College of Medical Genetics and Genomics (ACMG) as a top poster presented at their Annual Clinical Genetics Meeting. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160310005280/en/ New data on rare diseases demonstrate impact of delayed diagnosis and obstacles for patients and clinicians, including lack of information, time to diagnosis, and accessibility due to cost. (Photo: Business Wire) “Rare disease affects as many as 30 million people in the U.S. alone, and many of these patients and
Read more
March 10, 2016 Invitae Presents New Data Demonstrating High Concordance of Variant Classifications for BRCA1/2 Across Major Clinical Testing Laboratories
Platform talk given at 2016 ACMG Annual Clinical Genetics Meeting Invitae Corporation (NYSE:NVTA), a genetic information company, today presented an important study at the 2016 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, demonstrating that variant classifications in BRCA1 and BRCA2 are highly concordant across major clinical testing laboratories. In 2015, The New England Journal of Medicine published a report from the ClinGen consortium describing efforts to gather clinically observed genetic variants into a central public database called ClinVar. Today, ClinVar contains more than 170,000 de-identified records submitted by commercial and academic laboratories. Invitae is one of the top submitters of BRCA1, BRCA2, and other genetic data to ClinVar. The American Medical Association , the Institute of Medicine , and the National Institutes of Health all support the sharing of de-identified genetic information in order to advance the goals of
Read more
February 25, 2016 Invitae to Present a Dozen Posters and Presentations at the 2016 American College of Medical Genetics Annual Clinical Genetics Meeting
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced it will be presenting a dozen posters and presentations at the 2016 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Tampa, Florida . The titles and schedule of the Invitae posters and presentations are as follows: Short Course: Tuesday, March 8, 12:50 p.m. Eastern How to use OMIM: Let me count the ways | Presented by Dr. Robert Nussbaum, Invitae Platform Talks & Poster Presentations: Thursday, March 10, 9:15 a.m. – 12:00 p.m. Eastern Platform Talk: Don’t believe everything you hear: Variant classifications for BRCA1 and BRCA2 are highly concordant across major clinical testing laboratories | Presented by Steve Lincoln , Invitae Platform Talk: A change in perspective: BRCA1 and BRCA2 pathogenic variants in patients with GI cancers | Presented by Judith Hiemenga , Spectrum Poster #95: Detection of novel Alu insertions by next-generation sequencing of hereditary cancer
Read more
February 23, 2016 Invitae to Present at the Cowen and Company 36th Annual Health Care Conference
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that members of the company’s management team will present at the Cowen and Company 36th Annual Health Care Conference on Monday, March 7, 2016 at approximately 4:40 p.m. Eastern / 1:40 p.m. Pacific in Boston, Massachusetts . The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at invitae2016ir.q4web.com. A replay of the webcasts will be available shortly after the conclusion of the presentation and will be archived on the company’s website. About Invitae Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company
Read more
February 9, 2016 Invitae Announces Full Year 2015 Financial Results and 2016 Business Objectives
Met volume guidance in 2015 with approximately 19,000 billable tests demonstrating more than 400% year-over-year growth, reduced cost of goods sold in Q4 to under $700 per sample, delivered annual revenue of $8.4 million Planning to deliver 50,000-70,000 billable tests and expand menu to approximately 3,000 genes by the end of 2016 Hosting conference call at 4:45 pm ET / 1:45 pm PT Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the fourth quarter and full year ended December 31, 2015. The company met its volume guidance by delivering approximately 19,000 billable tests in the year and announced its plan to deliver 50,000-70,000 billable tests in 2016. “In 2015, we demonstrated our ability to scale our genetic testing business and proved a hypothesis that is fundamental to our future success: delivering comprehensive, high quality genetic testing at an affordable price resonates with clinicians and drives volume,” said Randy Scott , chairman and CEO
Read more
January 26, 2016 Invitae to Announce Fourth Quarter and Year-End 2015 Financial Results and Host Conference Call on February 9, 2016
SAN FRANCISCO-(BUSINESS WIRE)- Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it will report its fourth quarter and year-end 2015 financial results on Tuesday, February 9, 2016, and Invitae’s management team will host a conference call that day at 4:45 p.m. Eastern / 1:45 p.m. Pacific to discuss the financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 24115796. Invitae also announced that it will present at the Leerink Partners 5th Annual Global Healthcare Conference on Thursday, February 11, 2016 at 10:45 a.m. Eastern / 7:45 a.m. Pacific. The live, listen-only webcasts of both the conference call and presentation at Leerink may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcasts will be available shortly after the conclusions
Read more
January 8, 2016 Invitae Announces It Met Volume Guidance by Delivering Nearly 19,000 Billable Tests in 2015 and Sets Volume Guidance at 50,000-70,000 Billable Tests for 2016
Demonstrated scalability of business with more than 400% year-over-year growth Planning to expand menu to more than 3,000 genes by the end of 2016 Management to present at the 34th Annual JP Morgan Healthcare Conference Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it met its volume guidance of 17,000-19,000 billable tests delivered in 2015, delivering nearly 19,000 billable tests for the year, representing a greater than 400% increase from the more than 3,600 billable tests delivered in 2014. Invitae reported that it accessioned more than 20,000 samples in 2015. In the fourth quarter of 2015, Invitae delivered nearly 7,000 billable tests, representing a 36% increase over the third quarter of 2015, and accessioned nearly 8,000 samples. Invitae will report its financial results and other metrics during its fourth quarter and year-end 2015 conference call in February. Additionally, the company announced guidance for 2016, including plans to:
Read more

DISCLAIMER

The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.

FORWARD-LOOKING STATEMENTS

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements
NYSE: NVTA 16.70 -0.02 -0.12% Volume: 1,196,250 20 minute delay September 24, 2018

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com